Mostrar registro simples

dc.contributor.authorSchwengber, Wallace Kleinpt_BR
dc.contributor.authorMota, Laís Marquespt_BR
dc.contributor.authorNava, Carla Fernandapt_BR
dc.contributor.authorRodrigues, João Antônio Paimpt_BR
dc.contributor.authorZanella, André Borsattopt_BR
dc.contributor.authorKuchenbecker, Ricardo de Souzapt_BR
dc.contributor.authorScheffel, Rafael Selbachpt_BR
dc.contributor.authorMaia, Ana Luiza Silvapt_BR
dc.contributor.authorDora, José Miguel Silvapt_BR
dc.date.accessioned2025-02-21T06:52:41Zpt_BR
dc.date.issued2020pt_BR
dc.identifier.issn2359-3997pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/287518pt_BR
dc.description.abstractObjective: This study aimed to explore the patterns of radioactive iodine (RAI) use for differentiated thyroid cancer (DTC) in Brazil over the past 20 years. Materials and methods: A retrospective analysis of the DTC-related RAI prescriptions, from 2000 to 2018, retrieved from the Department of Informatics of the Unified Health System (Datasus) and National Supplementary Health Agency (ANS) database was performed. RAI activities prescriptions were re-classified as low (30-50 mCi), intermediate (100 mCi), or high activities (>100 mCi). Results: The number of DTC-related RAI prescriptions increased from 0.45 to 2.28/100,000 inhabitants from 2000 to 2015, declining onwards, closing 2018 at 1.87/100,000. In 2018, population-adjusted RAI prescriptions by state ranged from 0.07 to 4.74/100,000 inhabitants. Regarding RAI activities, in the 2000 to 2008 period, the proportion of high-activities among all RAI prescriptions increased from 51.2% to 74.1%. From 2009 onwards, there was a progressive reduction in high-activity prescriptions in the country, closing 2018 at 50.1%. In 2018, the practice of requesting high-activities varied from 16% to 82% between Brazilian states. Interestingly, variability of RAI use do not seem to be related to RAI referral center volume nor state socio-economic indicators. Conclusion: In recent years, there has been a trend towards the lower prescription of RAI, and a reduction of high-activity RAI prescriptions for DTC in Brazil. Also, significative inter-state and inter-institutional variability on RAI use was documented. These results suggest that actions to advance DTC healthcare quality surveillance should be prioritized.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofArchives of endocrinology and metabolism. São Paulo. Vol. 64, no. 6 (Nov./Dec. 2020), p. 824-832pt_BR
dc.rightsOpen Accessen
dc.subjectNeoplasias da glândula tireóidept_BR
dc.subjectDifferentiated thyroid carcinomaen
dc.subjectIsótopos de iodopt_BR
dc.subjectRadioiodineen
dc.subjectTreatmenten
dc.subjectQuimioterapia adjuvantept_BR
dc.subjectAnálise de dadospt_BR
dc.titlePatterns of radioiodine use for differentiated thyroid carcinoma in Brazil : insights and a call for action from a 20-year databasept_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001121168pt_BR
dc.type.originNacionalpt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples